Pfizer Inc. : Pfizer and BioNTech receive approval and authorization from the U. S. FDAU. S. Vaccine for the Omicron KP. 2 Adapted COVID-19 Vaccine

The approval is based on the totality of past clinical, non-clinical, and real-world evidence supporting the protection and efficacy of Pfizer and BioNTech’s COVID-19 vaccines. The application also included the production and non-clinical knowledge that appears to be the KP. 2 -adapted vaccine generates an especially accelerated reaction against the Omicron JN. 1 sublineages circulating lately, adding KP. 2, KP. 3 and LB. 1, to companies. ‘Omicron XBB. 1. 5 COVID-19. 3 Vaccine

INDICATION, AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

Before receiving COMIRNATY, tell your vaccine provider about any concerns about your physical status and add if:

AUTHORIZED USE

EMERGENCY USE AUTHORIZATION

IMPORTANT SAFETY INFORMATION

About Pfizer: Advances that change patients’ lives

Pfizer Disclosure Notice

About BioNTech

BioNTech’s Forward-Looking Statements

View businesswire. com edition: https://www. businesswire. com/news/home/20240821286745/en/

Contacts:

Korrektur as Einstiegschance

Nach höchstständen im Mai korrigierte das rote Metalll stark. The Abwärtsspirale extends to the United States and China. Langfristig könnte sich die aktuell laufende Korrektur als excellente Einstiegsmöglichkeit herausstellen.

3 cuts with

I recently came across an informal special report with three Australian agencies that one of them was making disproportionate profits.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Leave a Comment

Your email address will not be published. Required fields are marked *